The American journal of sports medicine · 2026
Intraoperative Zoledronic Acid for Arthroscopic Rotator Cuff Repair Results in Distinct Circulating Micro-RNA Profiles Indicating Improved Tendon-to-Bone Healing.
СтатьяРандомизированное исследованиеКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schanda Jakob E, Hackl Matthias, Bischl Romana, Ullrich Roman, Boesmueller Sandra, Mittermayr Rainer, Redl Heinz, Grillari Johannes, Fialka Christian
Аннотация
BACKGROUND: A prospective, randomized, placebo-controlled trial showed reduced retears after arthroscopic rotator cuff (RC) repair in patients without osteoporosis by a systemic single-dose of zoledronic acid. Distinct micro-ribonucleic acids (miRNAs) related to inflammation, fibrosis, and tendon-to-bone healing are associated with RC injuries.
PURPOSE: To investigate the longitudinal effects of a single-dose of zoledronic acid in patients without osteoporosis undergoing arthroscopic RC repair on circulating miRNAs in order to explore the molecular mechanism of this treatment.
STUDY DESIGN: Controlled laboratory study.
METHODS: Data were collected in the course of a single-center, prospective, randomized, placebo-controlled, triple-blinded (investigator, surgeon, patient) phase II trial. A total of 80 patients underwent arthroscopic RC repair and were intraoperatively randomized to the zoledronic acid group (n = 40) or the control group (n = 40). Circulating plasma miRNAs were assessed preoperatively, 2 days postoperatively, and 3 months postoperatively using small RNA sequencing and reverse transcription quantitative polymerase chain reaction (RT-qPCR).
RESULTS: Six miRNAs were selected for validation by RT-qPCR based on small RNA-sequencing analysis. No statistical differences in miRNA plasma levels were observed preoperatively between the 2 study groups. Two days after surgery, plasma levels were significantly lower for miR-140-3p (P = .047) in the zoledronic acid group. In the control group, plasma levels were significantly lower for miR-29a-3p (P < .001), miR-21-5p (P = .036), miR-192-5p (P = .034), and miR-146a-5p (P < .001) 2 days after surgery. Three months after surgery, miRNA plasma levels of the 2 study groups equalized without any significant differences. Gene target analysis identified collagen type I alpha 1 chain, collagen type III alpha 1 chain, vascular endothelial growth factor, insulin-like growth factor 1, and transforming growth factor-β1 as targets of miRNAs impacted by zoledronic acid.
CONCLUSION: Longitudinal plasma miRNA expressions suggest a molecular response to zoledronic acid, potentially indicating a reduction of inflammation and fibrosis at the enthesis as well as increased collagen synthesis and vascularization, possibly explaining improved tendon-to-bone healing.
CLINICAL RELEVANCE: Zoledronic acid is a safe and easy-to-apply augmentation technique for patients undergoing arthroscopic RC repair.
REGISTRATION: NCT05677152 (ClinicalTrials.gov identifier).
PURPOSE: To investigate the longitudinal effects of a single-dose of zoledronic acid in patients without osteoporosis undergoing arthroscopic RC repair on circulating miRNAs in order to explore the molecular mechanism of this treatment.
STUDY DESIGN: Controlled laboratory study.
METHODS: Data were collected in the course of a single-center, prospective, randomized, placebo-controlled, triple-blinded (investigator, surgeon, patient) phase II trial. A total of 80 patients underwent arthroscopic RC repair and were intraoperatively randomized to the zoledronic acid group (n = 40) or the control group (n = 40). Circulating plasma miRNAs were assessed preoperatively, 2 days postoperatively, and 3 months postoperatively using small RNA sequencing and reverse transcription quantitative polymerase chain reaction (RT-qPCR).
RESULTS: Six miRNAs were selected for validation by RT-qPCR based on small RNA-sequencing analysis. No statistical differences in miRNA plasma levels were observed preoperatively between the 2 study groups. Two days after surgery, plasma levels were significantly lower for miR-140-3p (P = .047) in the zoledronic acid group. In the control group, plasma levels were significantly lower for miR-29a-3p (P < .001), miR-21-5p (P = .036), miR-192-5p (P = .034), and miR-146a-5p (P < .001) 2 days after surgery. Three months after surgery, miRNA plasma levels of the 2 study groups equalized without any significant differences. Gene target analysis identified collagen type I alpha 1 chain, collagen type III alpha 1 chain, vascular endothelial growth factor, insulin-like growth factor 1, and transforming growth factor-β1 as targets of miRNAs impacted by zoledronic acid.
CONCLUSION: Longitudinal plasma miRNA expressions suggest a molecular response to zoledronic acid, potentially indicating a reduction of inflammation and fibrosis at the enthesis as well as increased collagen synthesis and vascularization, possibly explaining improved tendon-to-bone healing.
CLINICAL RELEVANCE: Zoledronic acid is a safe and easy-to-apply augmentation technique for patients undergoing arthroscopic RC repair.
REGISTRATION: NCT05677152 (ClinicalTrials.gov identifier).